Premium
AN ONGOING PHASE 1/1B TRIAL INVESTIGATING NOVEL TREATMENT REGIMENS WITH MOSUNETUZUMAB IN RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA
Author(s) -
Kim W.S.,
Assouline S.,
Bartlett N.L.,
Bosch F.,
Budde L.E.,
Cheah C.,
Gregory G.P.,
Hong J.,
Ku M.,
Marlton P.,
Matasar M.,
Nastoupil L.,
Panizo C.,
Sehn L.H.,
Tzachanis D.,
Chu W.,
Hernandez M.G.,
Kwan A.,
Li C.C.,
Sison I.,
Wei M.C.,
Yin S.,
Yousefi K.,
Yoon S.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.15_2632
Subject(s) - medicine , follicular lymphoma , tolerability , lymphoma , oncology , rituximab , dosing , mantle cell lymphoma , gastroenterology , adverse effect
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom